Location of Repository

The role of haptoglobin in phagocyte-mediated killing of Staphylococcus aureus

By Bassim Djebabri


Haptoglobin is a positive acute-phase serum protein. It is upregulated during infection and is a valuable marker for many inflammatory-related diseases. Its primary known function is to eliminate haemoglobin from plasma to prevent loss of iron through the kidneys, thereby protecting the kidneys from damage and sequestering iron, a key target for invading bacteria. In this thesis, I show that haptoglobin also interacts with lipoteichoic acid (LTA) of Staphylococcus aureus, an important virulence factor. Bacteria are subsequently eliminated by neutrophil-, monocyte- and macrophage-mediated killing.\ud S. aureus is an extremely common human pathogen associated with various diseases including septic arthritis and toxic-shock syndrome. A current major concern is the emergence of multidrug-resistant strains such as methicillin-resistant S. aureus (MRSA) that cause severe infections in hospitals and in the community. To increase our understanding of the defence mechanisms employed by the host against S. aureus, LTA was used to capture LTA-binding proteins from human serum and these were identified using a proteomics-based strategy. A variety of targets were captured including complement proteins, lipid-transport proteins, coagulation-cascade proteins and acute-phase proteins. Haptoglobin was selected for further study, because its expression is known to be upregulated in response to infection, and it interacts with phagocytic cells to stimulate phagocytosis. ELISA and column chromatography studies confirmed that haptoglobin binds LTA directly as well as S. aureus and suggest that the α-chain of haptoglobin is critical for this interaction.\ud The role of haptoglobin in promoting the killing of S. aureus by neutrophils, monocytes and macrophages was evaluated by comparing in vitro bacterial-killing using serum depleted of haptoglobin. For each cell type haptoglobin was found to be a key mediator in phagocyte-mediated bacterial killing. This work highlights an important new role for haptoglobin in immune defence, and explains its upregulation during infection

Publisher: University of Leicester
Year: 2010
OAI identifier: oai:lra.le.ac.uk:2381/8437

Suggested articles



  1. (2006). 1. Overview of the human immune response.
  2. (2006). 5. IgE, mast cells, basophils, and eosinophils.
  3. (2005). A
  4. (2002). A cathelicidin family of human antibacterial peptide LL-37 induces mast cell chemotaxis.
  5. (1994). A cell surface protein that binds avian hepatitis B virus particles.
  6. (2006). A clonogenic bone marrow progenitor specific for macrophages and dendritic cells.
  7. (2003). A continuum of anionic charge: structures and functions of D-alanyl-teichoic acids in gram-positive bacteria.
  8. (2005). A direct role for C1 inhibitor in regulation of leukocyte adhesion.
  9. (2008). A potential new pathway for Staphylococcus aureus dissemination: the silent survival of S. aureus phagocytosed by human monocyte-derived macrophages.
  10. (1987). A scanning electron microscopy study of human spleen: relationship between the microcirculation and functions.
  11. (2008). A shot in the arm for mast cells.
  12. (1995). A tumor-derived protein which provides T-cell costimulation through accessory cell activation.
  13. (2007). A unique loop extension in the serine protease domain of haptoglobin is essential for CD163 recognition of the haptoglobin-hemoglobin complex.
  14. (2003). Activation of influenza virus-specific CD4+ and CD8+ T cells: a new role for plasmacytoid dendritic cells in adaptive immunity.
  15. (2002). Activation of the lectin complement pathway by H-ficolin (Hakata antigen).
  16. (2005). Acute phase reaction and acute phase proteins.
  17. (1987). Adherence of Staphylococcus aureus to squamous epithelium: role of fibronectin and teichoic acid.
  18. (2004). Almost sharp fronts for the surface quasigeostrophic equation.
  19. (2000). Altered immune responses in apolipoprotein E-deficient mice.
  20. (2000). An essential role of mast cells in the development of airway hyperresponsiveness in a murine asthma model.
  21. (1968). An improved method of preparing haptoglobin polypeptide chains using guanidine hydrochloride. Proc Soc Exp Biol Med,
  22. (2000). An in vitro system for the enzymological analysis of avian hepatitis B virus replication and inhibition in core particles.
  23. (2006). An introduction to TRP channels.
  24. (1997). Analysis of the affinity of each haptoglobin polymer for hemoglobin by two-dimensional affinity electrophoresis.
  25. (1994). Analysis of the binding of a host cell surface glycoprotein to the preS protein of duck hepatitis B virus.
  26. (2004). Anti-microbial peptides: from invertebrates to vertebrates.
  27. (2001). Antibiotic resistance in postoperative infections.
  28. (1998). Antibiotic-induced release of bacterial cell wall components in the pathogenesis of sepsis and septic shock: a review.
  29. (1998). Antibiotic-induced release of lipoteichoic acid and peptidoglycan from Staphylococcus aureus: quantitative measurements and biological reactivities.
  30. (2004). Antioxidant role of human haptoglobin.
  31. (2002). Antithrombin III. Key factor in extracorporeal circulation.
  32. (2000). Apolipophorin-III and the interactions of lipoteichoic acids with the immediate immune responses of Galleria mellonella.
  33. (1999). Apolipophorin-III in Galleria mellonella potentiates hemolymph lytic activity.
  34. (2001). Apolipoprotein E protects against bacterial lipopolysaccharide-induced lethality. A new therapeutic approach to treat gram-negative sepsis.
  35. (1993). Apoptosis in human monocytes: possible role in chronic inflammatory diseases.
  36. (2000). B1 B lymphocytes play a critical role in host protection against lymphatic filarial parasites.
  37. (2005). Bacterial cell shape.
  38. (2003). Bacterial lipopolysaccharide decreases thrombomodulin expression in the sinusoidal endothelial cells of rats -- a possible mechanism of intrasinusoidal microthrombus formation and liver dysfunction.
  39. (2005). Biochemical characterization of plasma in amyotrophic lateral sclerosis: amino acid and protein composition.
  40. (1996). Biological and clinical significance of haptoglobin polymorphism in humans.
  41. (2007). C-reactive protein collaborates with plasma lectins to boost immune response against bacteria.
  42. (2004). C-reactive Protein.
  43. (1991). C1: molecular interactions with activating systems.
  44. (1998). Carboxypeptidase D (gp180), a Golgi-resident protein, functions in the attachment and entry of avian hepatitis B viruses.
  45. (2005). CCR2-positive monocytes recruited to inflamed lungs downregulate local CCL2 chemokine levels.
  46. (2004). CD163: a regulated hemoglobin scavenger receptor with a role in the anti-inflammatory response.
  47. (2007). Cell biology of polycystin-2.
  48. (1998). Cellular carboxypeptidases.
  49. (2000). Cellular receptor traffic is essential for productive duck hepatitis B virus infection.
  50. (1999). Characterization of a novel trypanosome lytic factor from human serum.
  51. (2003). Chymase-positive mast cells in small sized adenocarcinoma of the lung.
  52. (2008). Citrullination of CXCL8 by peptidylarginine deiminase alters receptor usage, prevents proteolysis, and dampens tissue inflammation.
  53. (1993). Cloning and characterization of a human Mac-2-binding protein, a new member of the superfamily defined by the macrophage scavenger receptor cysteine-rich domain.
  54. (1998). Cloning and characterization of the Hakata antigen, a member of the ficolin/opsonin p35 lectin family.
  55. (2009). Coagulation activation by lipopolysaccharides.
  56. (2002). Collectins and ficolins: sugar pattern recognition molecules of the mammalian innate immune system.
  57. (2007). Complement activating soluble pattern recognition molecules with collagen-like regions, mannan-binding lectin, ficolins and associated proteins.
  58. (1982). Complement activation by C-reactive protein complexes.
  59. (2005). Complement protein C1q recognizes a conformationally modified form of the prion protein.
  60. (1989). Control of immune complexes by the classical pathway.
  61. (1976). Control of the amplification convertase of complement by the plasma protein beta1H.
  62. (1999). Cullin-3 targets cyclin E for ubiquitination and controls S phase in mammalian cells.
  63. (2000). Current treatment of sepsis and endotoxaemia.
  64. (1994). Cyclin E controls S phase progression and its down-regulation during Drosophila embryogenesis is required for the arrest of cell proliferation.
  65. (1989). Cytokines as communication signals between leukocytes and endothelial cells.
  66. (1988). Damage to cell membranes by pore-forming bacterial cytolysins.
  67. (2001). de Paulis A
  68. (2006). Dectin-1: a signalling non-TLR pattern-recognition receptor.
  69. (2004). Defensin-mediated innate immunity in the small intestine.
  70. (1997). Deltatoxin from Staphylococcus aureus as a costimulator of human neutrophil oxidative burst.
  71. (1997). Difference in hemoglobin-binding ability of polymers among haptoglobin phenotypes.
  72. (1994). Differential binding of chemokines to glycosaminoglycan subpopulations.
  73. (2002). Disseminated candidiasis and hepatic malarial infection in mannose-binding-lectin-A-deficient mice.
  74. (2009). Do symbiotic bacteria subvert host immunity?
  75. (1999). Domain organization of Mac-2 binding protein and its oligomerization to linear and ring-like structures.
  76. Durrington PN (1993a) The role of high-density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation.
  77. Durrington PN (1993b) Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase.
  78. (2008). Ectromelia virus BTB/kelch proteins, EVM150 and EVM167, interact with cullin-3-based ubiquitin ligases.
  79. (2005). Effect of capsulation of opportunistic pathogenic bacteria on binding of the pattern recognition molecules mannan-binding lectin, L-ficolin, and H-ficolin.
  80. (1977). Effect of leukocyte hydrolases on bacteria. IX. The release of lipoteichoic acid from group A streptococci and from Strep. mutans by leukocyte extracts and by lysozyme: relation to tissue damage in inflammatory sites.
  81. (1993). Effect of mannose-binding protein on binding of Cryptococcus neoformans to human phagocytes.
  82. (2001). Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer.
  83. (2002). Enhanced activation of bound plasminogen on Staphylococcus aureus by staphylokinase.
  84. (2002). Eosinophil peroxidase produces hypobromous acid in the airways of stable asthmatics.
  85. (2006). Epithelial and mucosal gamma delta T cells.
  86. (1978). Excretion of lipoteichoic acid by group A streptococci. Influence of penicillin on excretion and loss of ability to adhere to human oral mucosal cells.
  87. (2000). Factor H binding to bone sialoprotein and osteopontin enables tumor cell evasion of complementmediated attack.
  88. (2007). Factor H binding to PspC of Streptococcus pneumoniae increases adherence to human cell lines in vitro and enhances invasion of mouse lungs in vivo.
  89. (1997). Fattom A
  90. (2004). Fibulins in development and heritable disease.
  91. (2003). Fibulins: a versatile family of extracellular matrix proteins.
  92. (2003). Fibulins: physiological and disease perspectives.
  93. (2007). Ficolin-2 recognizes DNA and participates in the clearance of dying host cells.
  94. (2008). Ficolins: novel pattern recognition molecules of the innate immune response.
  95. (2002). Functional studies on recombinant domains of Mac-2-binding protein.
  96. (2006). Gender difference in cytokine secretion on immune stimulation with LPS and LTA.
  97. (2002). Genetics and pathogenesis of polycystic kidney disease.
  98. Germino GG (2003) Role of polycystins in renal tubulogenesis.
  99. (1995). gp180, a host cell glycoprotein that binds duck hepatitis B virus particles, is encoded by a member of the carboxypeptidase gene family.
  100. (1999). Gram-positive sepsis. Mechanisms and differences from gram-negative sepsis.
  101. (1997). Granules of the human neutrophilic polymorphonuclear leukocyte.
  102. (1992). Granulocyte colony-stimulating factor: structure, function and physiology.
  103. (1997). Haemolymph proteins of larvae of Galleria mellonella detoxify endotoxins of the insect pathogenic bacteria Xenorhabdus nematophilus (Enterobacteriaceae).
  104. (2006). Haptoglobin 2-2 phenotype is a risk factor for type 2 diabetes in Ghana.
  105. (2003). Haptoglobin and its association with the HELLP syndrome.
  106. (2007). Haptoglobin genotype determines myocardial infarct size in diabetic mice.
  107. (2006). Haptoglobin is synthesized during granulocyte differentiation, stored in specific granules, and released by neutrophils in response to activation.
  108. (2004). Haptoglobin phenotypes in health and disorders.
  109. (2006). Haptoglobin-related protein is a high-affinity hemoglobin-binding plasma protein.
  110. (2001). Haptoglobin, an inflammation-inducible plasma protein.
  111. (2008). Haptoglobin, inflammation and disease.
  112. (2004). Haptoglobin: a major susceptibility gene for diabetic cardiovascular disease.
  113. (1995). HDL apolipoprotein A-I attenuates oxidative modification of low density lipoprotein: studies in transgenic mice.
  114. (1995). HDL, its enzymes and its potential to influence lipid peroxidation.
  115. (1990). Heparin-like glycosaminoglycan is a receptor for antithrombin III-dependent but not for thrombin-dependent prostacyclin production in human endothelial cells.
  116. (1996). High density lipoprotein and lipoprotein oxidation.
  117. (2001). High-density lipoprotein loses its anti-inflammatory properties during acute influenza a infection.
  118. (2004). Highly purified lipoteichoic acid activates neutrophil granulocytes and delays their spontaneous apoptosis via CD14 and TLR2.
  119. (2007). How human neutrophils kill and degrade microbes: an integrated view.
  120. (2007). How many infection control staff do we need in hospitals?
  121. (1977). Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution.
  122. (1995). Human cyclin E, a nuclear protein essential for the G1-to-S phase transition.
  123. (2008). Human haptoglobin structure and function--a molecular modelling study.
  124. (2001). Human IgA activates the complement system via the mannan-binding lectin pathway.
  125. (2005). Human M-ficolin is a secretory protein that activates the lectin complement pathway.
  126. (2002). Humoral immune response for early diagnosis of breast carcinoma.
  127. (2009). Humoral pattern recognition molecules: mannan-binding lectin and ficolins.
  128. (1989). Identification and characterization of a novel monocyte subpopulation in human peripheral blood.
  129. (1997). Identification of a membrane-bound carboxypeptidase as the mammalian homolog of duck gp180, a hepatitis B virus-binding protein.
  130. (2002). Identification of breast cancer-restricted antigens by antibody screening of SKBR3 cDNA library using a preselected patient's serum.
  131. (2001). Identification of the haemoglobin scavenger receptor.
  132. (1992). IL-4 enhances programmed cell death (apoptosis) in stimulated human monocytes.
  133. (2005). Immune evasion by staphylococci.
  134. (1981). Immunofluorescence studies on the subcomponents of the first component of complement (C1): detection of C1q and C1s in different cells of biopsy material and on human as well as on guinea pig peritoneal macrophages.
  135. (2004). Immunological and pathobiological roles of fibulin-1 in breast cancer.
  136. (2008). Immunological mechanisms underlying the genetic predisposition to severe Staphylococcus aureus infection in the mouse model.
  137. (2001). Immunological therapy in sepsis: currently available.
  138. (2001). Immunological therapy of sepsis: experimental therapies.
  139. (1990). Increase in National Hospital Discharge Survey rates for septicemia--United States,
  140. (1992). Induction of nitric oxide synthase by lipoteichoic acid from Staphylococcus aureus in vascular smooth muscle cells.
  141. (2004). Inhibition of intravascular thrombosis in murine endotoxemia by targeted expression of hirudin and tissue factor pathway inhibitor analogs to activated endothelium.
  142. (2006). Innate immune recognition of viral infection.
  143. (2002). Innate immune recognition.
  144. (1997). Innate immunity: impact on the adaptive immune response.
  145. (2000). Innate immunity.
  146. (2002). Integration of inflammatory signals by rolling neutrophils.
  147. (1995). Interaction between duck hepatitis B virus and a 170-kilodalton cellular protein is mediated through a neutralizing epitope of the preS region and occurs during viral infection.
  148. (2000). Interaction of mannose-binding protein with associated serine proteases: effects of naturally occurring mutations.
  149. (2002). Interactions between lipoteichoic acid and peptidoglycan from Staphylococcus aureus: a structural and functional analysis.
  150. (1994). Interactions of carbohydrates and lectins with complement.
  151. (1996). Interactions of human mannose-binding protein with lipoteichoic acids.
  152. (1990). Interference with immune response at the level of generating effector cells by tumor-associated haptoglobin.
  153. (2003). Interleukin-12 and the regulation of innate resistance and adaptive immunity.
  154. (1998). Interleukin-6 and related cytokines: effect on the acute phase reaction.
  155. (1998). Internalization study using EDTA-prepared hepatocytes for receptor-mediated endocytosis of haemoglobin-haptoglobin complex.
  156. (2006). Intracellular pattern recognition receptors in the host response.
  157. (2004). Iron-regulated surface determinants (Isd) of Staphylococcus aureus: stealing iron from heme.
  158. (2004). Iron-source preference of Staphylococcus aureus infections.
  159. (1965). Isolation of Beta If-Globulin from Human Serum and Its Characterization as the Fifth Component of Complement.
  160. (1982). Kinetic aspects of hemoglobin.haptoglobin-receptor interaction in rat liver plasma membranes, isolated liver cells, and liver cells in primary culture.
  161. (2004). L-ficolin is a pattern recognition molecule specific for acetyl groups.
  162. (2004). L-ficolin specifically binds to lipoteichoic acid, a cell wall constituent of Gram-positive bacteria, and activates the lectin pathway of complement.
  163. (2008). Lipopolysaccharide is a frequent and significant contaminant in microglia-activating factors.
  164. (1994). Lipopolysaccharide-lipophorin complex formation in insect hemolymph: a common pathway of lipopolysaccharide Bibliography 186 detoxification both in insects and in mammals.
  165. (2000). Lipoproteins modify the macrophage uptake of triacylglycerol emulsion and of zymosan particles by similar mechanisms.
  166. (1996). Liposome-encapsulated dichloromethylene diphosphonate induces macrophage apoptosis in vivo and in vitro.
  167. (1994). Lipoteichoic acid and lipids in the membrane of Staphylococcus aureus.
  168. (1998). Lipoteichoic acid and protein-A from Staphylococcus aureus stimulate release of hepatocyte growth factor
  169. (1981). Lipoteichoic acid inhibition of phagocytosis of Staphylococcus aureus by human polymorphonuclear leukocytes.
  170. (1995). LPS-dependent interaction of Mac-2-binding protein with immobilized CD14.
  171. (1989). Lysis of Trypanosoma brucei by a toxic subspecies of human high density lipoprotein.
  172. (2000). M-ficolin is expressed on monocytes and is a lectin binding to N-acetyl-D-glucosamine and mediates monocyte adhesion and phagocytosis of Escherichia coli.
  173. (1998). Mac-2 binding protein is a celladhesive protein of the extracellular matrix which self-assembles into ring-like structures and binds beta1 integrins, collagens and fibronectin.
  174. (2007). Macrophage complement receptors and pathogen clearance.
  175. (2008). Macrophage differentiation and function in health and disease.
  176. (2005). Macrophage receptors and immune recognition.
  177. (1996). Macrophages, NK cells and neutrophils in the cytokine loop of Listeria resistance.
  178. (2005). Mammalian defensins in the antimicrobial immune response.
  179. (2000). Mannosebinding lectin binds to a range of clinically relevant microorganisms and promotes complement deposition.
  180. (2008). Mantovani A
  181. (1993). Mast cell activation enhances airway responsiveness to methacholine in the mouse.
  182. (2007). Mast cells in the promotion and limitation of chronic inflammation.
  183. (2002). Mechanism and kinetics of delta-lysin interaction with phospholipid vesicles.
  184. (1998). Mechanism of gram-positive shock: identification of peptidoglycan and lipoteichoic acid moieties essential in the induction of nitric oxide synthase, shock, and multiple organ failure.
  185. (1997). Mechanism of suppression of macrophage nitric oxide release by IL-13: influence of the macrophage population.
  186. (1999). Mechanisms of phagocytosis in macrophages.
  187. (2001). Mechanisms underlying ubiquitination.
  188. (1996). Membrane anchoring and release of carboxypeptidase M: implications for extracellular hydrolysis of peptide hormones.
  189. (2006). Migratory fate and differentiation of blood monocyte subsets.
  190. (1987). Modelling of C1, the first component of human complement: towards a consensus?
  191. (1976). Modulation of the alternative complement pathways by beta 1 H globulin.
  192. Moestrup SK (2002) CD163: a signal receptor scavenging haptoglobin-hemoglobin complexes from plasma.
  193. (2001). Molecular genetics and pathogenesis of autosomal dominant polycystic kidney disease.
  194. (1988). Molecular organization and function of the complement system.
  195. (1994). Monocyte adhesion and transmigration in atherosclerosis.
  196. (2007). Monocyte subpopulations and their differentiation patterns during infection.
  197. (2005). Moretta A
  198. (2003). MYH9 spectrum of autosomaldominant giant platelet syndromes: unexpected association with fibulin-1 variant-D inactivation.
  199. (2000). Natural interferon alpha/betaproducing cells link innate and adaptive immunity.
  200. (2002). Natural killer cell receptor expression by human first trimester decidual granular leukocytes and T-lymphocytes.
  201. (2002). Natural killer cells and dendritic cells: rendezvous in abused tissues.
  202. (1999). Natural killer cells in antiviral defense: function and regulation by innate cytokines.
  203. (1991). Nephrotoxic potential of Bence Jones proteins.
  204. (2001). Neural route of cerebral Listeria monocytogenes murine infection: role of immune response mechanisms in controlling bacterial neuroinvasion.
  205. (1999). Neutrophil antibacterial peptides, multifunctional effector molecules in the mammalian immune system.
  206. (2008). Neutrophil elastase, proteinase 3 and cathepsin G: physicochemical properties, activity and physiopathological functions.
  207. (2004). Neutrophil extracellular traps kill bacteria.
  208. (1992). New perspectives on the structure and function of transferrins.
  209. (1970). Normal blood leukocyte concentration values.
  210. (1974). Normal laboratory values for differential white cell counts established by manual and automated cytochemical methods (Hemalog D-TM).
  211. (1998). Novel anti-staphylococcal targets and compounds.
  212. (1985). Nucleotide sequence of the haptoglobin and haptoglobin-related gene pair. The haptoglobin-related gene contains a retrovirus-like element.
  213. (1972). Observations on human monocyte kinetics after pulse labeling.
  214. (1991). Oligomeric domain structure of human complement factor H by X-ray and neutron solution scattering.
  215. (2000). Opsonic function and concentration of human serum ficolin/P35.
  216. (2002). Optimization of the cell wall microenvironment allows increased production of recombinant Bacillus anthracis protective antigen from B. subtilis.
  217. (2002). Overproduction of type 8 capsular polysaccharide augments Staphylococcus aureus virulence.
  218. (2002). Oxidative stress increases the expression of
  219. (2005). Oxysterol-induced up-regulation of MCP-1 expression and synthesis in macrophage cells.
  220. (2002). Ozinsky A
  221. (1999). P35, an opsonic lectin of the ficolin family, in human blood from neonates, normal adults, and recurrent miscarriage patients.
  222. (2005). Paraoxonase 1 (PON1) enhances HDLmediated macrophage cholesterol efflux via the ABCA1 transporter in association with increased HDL binding to the cells: a possible role for lysophosphatidylcholine.
  223. (1991). Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein.
  224. (1988). Passive sensitization and antigen challenge increase vascular permeability in rat airways. Am Rev Respir Dis,
  225. (1996). Passive transfer of immediate hypersensitivity and airway hyperresponsiveness by allergen-specific immunoglobulin (Ig) E and IgG1 in mice.
  226. (2006). Pathogen recognition and innate immunity.
  227. (1994). Pathogenesis and treatment of myeloma kidney.
  228. (2002). Pathways for bradykinin formation and inflammatory disease.
  229. (2002). Pattern recognition receptors: doubling up for the innate immune response.
  230. (2000). Peptidoglycan and lipoteichoic acid from Staphylococcus aureus induce tumor necrosis factor alpha, interleukin 6 (IL-6), and IL-10 production in both T cells and monocytes in a human whole blood model.
  231. (2003). Peptidoglycan and lipoteichoic acid in gram-positive bacterial sepsis: receptors, signal transduction, biological effects, and synergism.
  232. (2001). Perinatal lethality and endothelial cell abnormalities in several vessel compartments of fibulin-1-deficient mice.
  233. (2010). Peschel A
  234. (1999). Phages for methicillin-resistant Staphylococcus aureus: an international trial.
  235. (2008). Phagocytosis and comparative innate immunity: learning on the fly.
  236. (2002). Phagocytosis and innate immunity.
  237. (1993). Phagocytosis of antigens by Langerhans cells in vitro.
  238. (2005). Phagocytosis: elegant complexity.
  239. (1998). Phase I/II trial of PIXY321 (granulocyte-macrophage colony stimulating factor/interleukin-3 fusion protein) for treatment of inherited and acquired marrow failure syndromes.
  240. (1999). Phylogenetic perspectives in innate immunity.
  241. (1996). PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein.
  242. (2003). Plasma-cell homing.
  243. (2005). Plasmacytoid dendritic cells: linking innate and adaptive immunity.
  244. (2001). Polycystin: new aspects of structure, function, and regulation.
  245. (2005). Polymorphisms in the FCN2 gene determine serum variation and function of Ficolin-2. Hum
  246. (1990). Polysaccharide-protein conjugates: a new generation of vaccines.
  247. (1997). Primary inherited defects in neutrophil function: etiology and treatment.
  248. (2007). Prion protein activates and fixes complement directly via the classical pathway: implications for the mechanism of scrapie agent propagation in lymphoid tissue.
  249. (1993). Prognostic value of a novel circulating serum 90K antigen in HIV-infected haemophilia patients.
  250. (1975). Properdin: initiation of alternative complement pathway.
  251. (2009). Protein gel staining methods: an introduction and overview.
  252. (1983). Proteins involved in the activation and control of the two pathways of human complement.
  253. (2000). Proteolytic activities of two types of mannose-binding lectin-associated serine protease.
  254. (1995). Purification and characterization of carboxypeptidase D, a novel carboxypeptidase E-like enzyme, from bovine pituitary.
  255. (2003). Putative ligands for a cytosolic beta-galactoside lectin.
  256. (1966). Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia.
  257. (1988). Rat IL-3 stimulates the growth of rat mucosal mast cells in culture.
  258. (1994). Raz A
  259. (1988). Recombinant human leukocyte interferon-alpha 2b stimulates the synthesis and release of a 90K tumorassociated antigen in human breast cancer cells.
  260. (1978). Regulation by membrane sialic acid of beta1H-dependent decaydissociation of amplification C3 convertase of the alternative complement pathway.
  261. (2004). Regulation of leukocyte transmigration: cell surface interactions and signaling events.
  262. (1993). Regulation of the acute phase response by cytokines.
  263. (1989). Release of interleukin-1 beta associated with potent cytocidal action of staphylococcal alpha-toxin on human monocytes.
  264. (2000). Release of teichoic and lipoteichoic acids from 30 different strains of Streptococcus pneumoniae during exposure to ceftriaxone, meropenem, quinupristin/dalfopristin, rifampicin and trovafloxacin.
  265. (1995). Role for circulating lipoproteins in protection from endotoxin toxicity.
  266. (2005). Role of L-ficolin/mannose-binding lectin-associated serine protease complexes in the opsonophagocytosis of type III group B streptococci.
  267. (2003). Role of Pseudomonas putida tol-oprL gene products in uptake of solutes through the cytoplasmic membrane.
  268. (2000). Secretion of microbicidal alpha-defensins by intestinal Paneth cells in response to bacteria.
  269. (2004). Serum haptoglobin: a novel marker of adiposity in humans.
  270. (2001). Shape and shift changes related to the function of leukocyte integrins LFA-1 and Mac-1.
  271. (2007). Sher A
  272. (1999). Specific association of the gene product of PKD2 with the TRPC1 channel.
  273. (2005). Specific binding of L-ficolin and H-ficolin to apoptotic cells leads to complement activation.
  274. (2002). Staphylococcal alpha-toxin synergistically enhances inflammation caused by bacterial components.
  275. (2004). Staphylococcus aureus capsular polysaccharides.
  276. (1998). Staphylococcus aureus infections.
  277. (1992). Staphylococcus aureus microcapsule expression attenuates bacterial virulence in a rat model of experimental endocarditis.
  278. (1998). Staphylococcus aureus serotype 5 capsular polysaccharide is antiphagocytic and enhances bacterial virulence in a murine bacteremia model.
  279. (1998). Staphylococcus aureus: a well-armed pathogen.
  280. (1980). Stimulation of lysosomal enzyme release from macrophages by lipoteichoic acid.
  281. (2006). Streptococcus pneumoniae recruits complement factor H through the amino terminus of CbpA.
  282. (2002). Structural and functional aspects of C1-inhibitor.
  283. (2002). Structural decomposition and heterogeneity of commercial lipoteichoic Acid preparations.
  284. (1984). Structure and assembly of haptoglobin polymers by electron microscopy.
  285. (2001). Structure-function relationship of cytokine induction by lipoteichoic acid from Staphylococcus aureus.
  286. (1993). Subcellular localization and dynamics of Mac-1 (alpha m beta 2) in human neutrophils.
  287. (1994). Subcellular localization and translocation of the receptor for N-formylmethionyl-leucyl-phenylalanine in human neutrophils.
  288. (1997). Suppression of anchorage-independent growth and matrigel invasion and delayed tumor formation by elevated expression of fibulin-1D in human fibrosarcoma-derived cell lines.
  289. (2007). Surolia A
  290. (2000). Survival of Staphylococcus aureus inside neutrophils contributes to infection.
  291. (2000). Systemic activation of basophils and eosinophils: markers and consequences.
  292. (2004). T cell proliferation by direct cross-talk between OX40 ligand on human mast cells and OX40 on human T cells: comparison of gene expression profiles between human tonsillar and lungcultured mast cells.
  293. (2005). Targeting leukocyte integrins in human diseases.
  294. (2005). Targeting of host-cell ubiquitin pathways by viruses.
  295. (1997). Tarkowski A
  296. (2007). The 60th symposium of the Society of General Physiologists. Chemotaxis, invasion, and phagocytosis: from bacteria to humans. (Organised by Sergio Grinstein
  297. (2005). The acute phase protein haptoglobin is a mammalian extracellular chaperone with an action similar to clusterin.
  298. (2008). The acute phase protein haptoglobin regulates host immunity.
  299. (1998). The anti-inflammatory properties of antithrombin III: new therapeutic implications.
  300. (1980). The Clq receptor site on immunoglobulin
  301. (2004). The complement system in regulation of adaptive immunity.
  302. (1988). The effect of interleukin-1, interleukin-6 and its interrelationship on the synthesis of serum amyloid A and C-reactive protein in primary cultures of adult human hepatocytes.
  303. (1996). The etiology, pathogenesis, and treatment of autosomal dominant polycystic kidney disease: recent advances.
  304. (1996). The expanding universe of T-cell subsets: Th1, Th2 and more.
  305. (1998). The heparan sulfate binding sequence of interferon-gamma increased the on rate of the interferon-gamma-interferongamma receptor complex formation.
  306. (2000). The human antimicrobial and chemotactic peptides LL-37 and alpha-defensins are expressed by specific lymphocyte and monocyte populations.
  307. (2000). The immunoglobulin superantigen-binding site of HIV-1 gp120 activates human basophils.
  308. (2000). The macrophage haunted by cell ghosts: a pathogen grows.
  309. (2002). The mannan-binding lectin-associated serine proteases (MASPs) and MAp19: four components of the lectin pathway activation complex encoded by two genes.
  310. (1986). The mitogenic properties of lipoteichoic acid from Staphylococcus aureus.
  311. (1972). The mononuclear phagocyte system: a new classification of macrophages, monocytes, and their precursor cells.
  312. (1988). The mortality of hospital-acquired bloodstream infections: need for a new vital statistic?
  313. (1993). The novel subset of CD14+/CD16+ blood monocytes exhibits features of tissue macrophages.
  314. (1968). The origin and kinetics of mononuclear phagocytes.
  315. (2004). The origin of hematopoietic cell type diversity.
  316. (2008). The origins of the identification and isolation of hematopoietic stem cells, and their capability to induce donor-specific transplantation tolerance and treat autoimmune diseases.
  317. (2008). The phagocytes: neutrophils and monocytes.
  318. (2004). The role of eosinophils in host defense against helminth parasites.
  319. (2005). The role of eosinophils in the pathogenesis of asthma.
  320. (2007). The role of vascular cell adhesion molecule-1 in tumor immune evasion.
  321. (1994). The secreted tumor-associated antigen 90K is a potent immune stimulator.
  322. (1995). The selectins: vascular adhesion molecules.
  323. (1989). The septic syndrome. Definition and clinical implications.
  324. (1999). The staphylococcal transferrin-binding protein is a cell wall glyceraldehyde-3-phosphate dehydrogenase.
  325. (2002). The TRP channels, a remarkably functional family.
  326. (1999). The ubiquitin system in gametogenesis.
  327. (2001). Themes and variations on ubiquitylation.
  328. (2004). Toll-like receptor 2-dependent bacterial sensing does not occur via peptidoglycan recognition.
  329. (2000). Toll-like receptors in the induction of the innate immune response.
  330. (1979). Tomasz A
  331. (2002). Transferrin binding in Staphylococcus aureus: involvement of a cell wall-anchored protein.
  332. (1985). Transmembrane channel-formation by five complement proteins.
  333. (1996). Trends in infectious diseases mortality in the United States.
  334. (2009). Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation.
  335. (1968). Viable counts of bacteria--a new method for facultative anaerobes.
  336. (2003). Viruses and the 26S proteasome: hacking into destruction.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.